Why Cognitive Peptides Are Attracting Research Attention

The neuropeptide research space has expanded significantly over the past decade, driven by growing scientific interest in neuroplasticity, neuroinflammation, and peptide-based approaches to cognitive function. Unlike small-molecule compounds, peptides can be designed with high target specificity and — in some cases — engineered to cross the blood-brain barrier or be administered intranasally to achieve central nervous system effects.

In Australia, cognitive and nootropic peptides occupy a relatively uncrowded research niche compared to the weight loss or tissue repair categories. Search volume is lower, but keyword difficulty is also substantially lower, meaning this content tends to rank more easily. More importantly, researchers in this space tend to be highly informed and actively seeking quality domestic sources.

Selank

Selank is a synthetic heptapeptide (7 amino acids) developed in Russia by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analogue of the endogenous tetrapeptide tuftsin, with additional modifications that extend its half-life and CNS bioavailability.

The primary research interest in Selank centres on its anxiolytic (anti-anxiety) effects and cognitive enhancement properties in animal models. Studies have investigated its influence on GABA receptor modulation, serotonin metabolism, and brain-derived neurotrophic factor (BDNF) expression. Some research has documented improved learning and memory performance in rodent models alongside reduced anxiety-related behaviours.

Selank is typically administered intranasally in research contexts — nasal spray formulations allow the peptide to bypass the blood-brain barrier via the olfactory pathway. It is not scheduled under Australia’s Poisons Standard and is available for research purposes domestically without a prescription.

Semax

Semax is a synthetic analogue of the adrenocorticotropic hormone (ACTH) fragment 4-7, extended with a Pro-Gly-Pro sequence that significantly increases its CNS stability and duration of action. Like Selank, it was developed in Russia and has a substantial Russian research literature, though it is less represented in English-language peer-reviewed journals.

Research interest in Semax focuses on its neuroprotective properties and its apparent ability to stimulate BDNF production. BDNF (Brain-Derived Neurotrophic Factor) is a critical growth factor for neuronal survival, synaptic plasticity, and the formation of new neural connections. Animal models have documented increased BDNF expression following Semax administration, alongside improved performance in cognitive tasks.

Semax has also been studied in stroke and brain injury models, where its neuroprotective effects have been investigated in the context of acute neuronal damage. It is not currently scheduled in Australia and is available for research purposes domestically.

Dihexa

Dihexa is a small peptide derived from angiotensin IV, developed by researchers at Washington State University. It has attracted significant research interest due to its extraordinary potency in synaptic connectivity studies — research has suggested it may be several orders of magnitude more potent than BDNF itself in promoting the formation of new synaptic connections (synaptogenesis) in certain animal models.

The research literature on Dihexa remains early-stage and primarily preclinical. The compounds acts on hepatocyte growth factor (HGF) and its receptor c-Met, a signalling pathway increasingly implicated in cognitive function and neuroprotection. Dihexa is an emerging research compound with no scheduled status in Australia.

Epithalon

Epithalon (also written as Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It has been studied primarily in the context of telomere biology — research has suggested it may activate telomerase, the enzyme responsible for maintaining telomere length, which has implications for cellular ageing research.

Beyond telomere biology, Epithalon has been studied for its effects on melatonin production, sleep regulation, and antioxidant activity. It represents the intersection of the cognitive peptide and longevity research categories and is not scheduled in Australia.

Key Considerations for Cognitive Peptide Research

Researchers working with CNS-active peptides face unique considerations that differ from tissue repair or metabolic research:

• Administration route matters significantly. Many cognitive peptides have limited oral bioavailability and are primarily studied via intranasal or injectable routes in research contexts. Researchers should verify which formulations are appropriate for their specific protocols.
• The research literature is geographically concentrated. Much of the foundational research on Selank and Semax was conducted in Russian-language journals. Researchers should be aware that English-language peer review of these compounds is more limited than for compounds with Western pharmaceutical backing.
• Blood-brain barrier penetration is a key variable. Peptide size and modification significantly affect CNS bioavailability. Researchers should understand the pharmacokinetic profiles of the specific compounds they are studying.

Sourcing Cognitive Peptides in Australia

All of the compounds discussed in this guide are available for research purposes from domestic Australian suppliers without a prescription, as none are currently scheduled under the Poisons Standard. Quality standards remain as demanding as for any research peptide — independent HPLC purity data, batch-specific CoAs, and mass spectrometry confirmation are essential regardless of the compound.

Intranasal formulations (nasal spray preparations) are available for some cognitive peptides including Selank and Semax, in addition to standard lyophilised powder. Researchers should confirm that nasal spray formulations meet the same purity standards as injectable-grade material.